PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 2109217
PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 2109217
India Biosimilars Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026 - 2035
India Biosimilars Market was valued at USD 1.5 billion in 2025 and is estimated to grow at a CAGR of 17.8% to reach USD 8.1 billion by 2035.
Market expansion is fueled by the increasing prevalence of chronic diseases, rising demand for affordable biologic therapies, and continued government support for the growth of the domestic biopharmaceutical sector. India's large patient population requiring advanced biologic treatment continues to create significant demand for lower-cost therapeutic alternatives. The high cost of biologic medicines remains a major challenge for healthcare accessibility, strengthening the role of biosimilars in expanding treatment availability across the country. In addition, India's well-established manufacturing infrastructure, cost-efficient production capabilities, and growing investments in biologic drug development continue to support market growth. Favorable regulatory improvements and government-led healthcare initiatives are further encouraging broader biosimilar adoption across multiple therapeutic areas. The India biosimilars market is also benefiting from rising healthcare spending, expanding patient access to advanced therapies, and increasing awareness among healthcare providers and patients regarding the clinical value of biosimilars. Strong domestic manufacturing capabilities and an efficient production ecosystem continue to reinforce the country's position as a leading biosimilars producer while supporting long-term market expansion.
| Market Scope | |
|---|---|
| Start Year | 2025 |
| Forecast Year | 2026-2035 |
| Start Value | $1.5 Billion |
| Forecast Value | $8.1 Billion |
| CAGR | 17.8% |
The recombinant glycosylated proteins segment accounted for a 69.4% share in 2025, maintaining its leading position due to the extensive use of these therapies in the management of chronic and complex diseases. Increasing demand for advanced biologic treatments across India's healthcare system has supported widespread adoption of recombinant glycosylated proteins in hospitals, specialty clinics, and tertiary care facilities. Their expanding role in improving treatment accessibility and addressing long-term disease management requirements continues to drive sustained growth within this segment.
The in-house segment reached USD 1 billion in 2025. The segment's leadership is supported by the presence of well-established domestic biopharmaceutical manufacturers with integrated capabilities across product development, manufacturing, quality management, and commercialization. Internal production allows companies to maintain greater control over manufacturing processes, improve operational efficiency, and ensure compliance with evolving regulatory standards. Continued investments in advanced biologics manufacturing facilities and production technologies are further strengthening in-house manufacturing capabilities while supporting reliable product supply and long-term business growth.
Major companies operating in the India biosimilars market include Aurobindo Pharma, Biocon Biologics, Dr. Reddy's Laboratories, Emcure Pharmaceuticals, Hetero Biopharma, Intas Pharmaceuticals, Lupin Limited, Reliance Life Sciences, Sun Pharmaceutical Industries, Torrent Pharmaceuticals, Viatris India, Wockhardt Limited, Zydus Lifesciences, Cadila Pharmaceuticals, and Stelis Biopharma. Companies operating in the India biosimilars market focus on expanding manufacturing capacity, strengthening research and development capabilities, and accelerating product pipeline development to enhance their market position. Leading players continue to invest in advanced production technologies and process optimization to improve product quality, operational efficiency, and regulatory compliance. Strategic collaborations, licensing agreements, and partnerships with healthcare organizations help broaden commercial reach and support faster product adoption. Businesses also prioritize expanding their domestic and international distribution networks to access new growth opportunities.
Table of Contents
Chapter 1 Methodology and Scope
- 1.1 Market scope and definition
- 1.2 Research approach
- 1.3 Quality commitments
- 1.3.1 GMI AI policy and data integrity commitment
- 1.3.1.1 Source consistency protocol
- 1.3.1 GMI AI policy and data integrity commitment
- 1.4 Research trail and confidence scoring
- 1.4.1 Research trail components
- 1.4.2 Scoring components
- 1.5 Data collection
- 1.5.1 Partial list of primary sources
- 1.6 Data mining sources
- 1.6.1 Paid sources
- 1.7 Base estimates and calculations
- 1.7.1 Revenue share analysis
- 1.7.2 Base year calculation
- 1.8 Forecast model
- 1.9 Research transparency addendum
- 1.9.1 Source attribution framework
- 1.9.2 Quality assurance metrics
- 1.9.3 Our commitment to trust
Chapter 2 Executive Summary
- 2.1 Industry 360° synopsis
- 2.2 Key market trends
- 2.2.1 Business trends
- 2.2.2 Product trends
- 2.2.3 Application trends
- 2.2.4 Manufacturing type trends
- 2.2.5 Technology trends
- 2.2.6 Distribution channel trends
- 2.3 CXO perspectives: Strategic imperatives
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Rising chronic disease burden
- 3.2.1.2 Strong domestic manufacturing capabilities
- 3.2.1.3 Government support and policy initiatives
- 3.2.1.4 High cost of originator biologics
- 3.2.2 Industry pitfalls and challenges
- 3.2.2.1 Limited penetration beyond urban centers
- 3.2.2.2 Complex development and regulatory requirements
- 3.2.3 Market opportunities
- 3.2.3.1 Expansion into global regulated markets
- 3.2.3.2 Advancements in bioprocessing and manufacturing technologies
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape (Driven by primary research)
- 3.5 Technology landscape
- 3.5.1 Current technological trends
- 3.5.2 Emerging technologies
- 3.6 Porter's analysis
- 3.7 Pricing analysis, by product (2025)
- 3.8 PESTEL analysis
- 3.9 Impact of AI and generative AI on the market (Driven by primary research)
- 3.10 Reimbursement landscape
- 3.11 Biosimilar litigation landscape
- 3.12 Future market trends (Driven by primary research)
- 3.13 Biosimilar factor analysis
- 3.13.1 Access
- 3.13.2 Regulations
- 3.13.3 Payer assessment and access
- 3.13.4 Physician acceptance
- 3.13.5 Patient acceptance
- 3.14 Biosimilar product pipeline analysis
- 3.15 Biosimilars approval scenario, 2022 - 2025
- 3.16 Biologics patent expiry scenario
- 3.17 International policies on the use of biosimilar drugs
- 3.17.1 Interchangeability, switching and substitution
- 3.17.2 Supply side policies
- 3.17.3 Prescribing incentives
Chapter 4 Competitive Landscape, 2025
- 4.1 Introduction
- 4.2 Company market share analysis
- 4.3 Company matrix analysis
- 4.4 Competitive analysis of major market players
- 4.5 Competitive positioning matrix
- 4.6 Key developments
- 4.6.1 Mergers and acquisitions
- 4.6.2 Partnerships and collaborations
- 4.6.3 New product launches
- 4.6.4 Expansion plans
Chapter 5 Market Estimates and Forecast, By Product, 2022-2035 ($ Mn)
- 5.1 Key trends
- 5.2 Recombinant non-glycosylated proteins
- 5.2.1 Human growth hormone
- 5.2.2 Granulocyte colony-stimulating factor (filgrastim)
- 5.2.3 Insulin
- 5.2.4 Interferon
- 5.2.4.1 Alfa
- 5.2.4.2 Beta
- 5.3 Recombinant glycosylated proteins
- 5.3.1 Monoclonal antibodies
- 5.3.1.1 Infliximab
- 5.3.1.2 Rituximab
- 5.3.1.3 Adalimumab
- 5.3.1.4 Trastuzumab
- 5.3.1.5 Bevacizumab
- 5.3.2 Erythropoietin
- 5.3.2.1 Alfa
- 5.3.2.2 Beta
- 5.3.3 Follitropin
- 5.3.3.1 Alfa
- 5.3.3.2 Beta
- 5.3.4 Fusion proteins
- 5.3.1 Monoclonal antibodies
- 5.4 Other products
Chapter 6 Market Estimates and Forecast, By Application, 2022-2035 ($ Mn)
- 6.1 Key trends
- 6.2 Hematology
- 6.2.1 Neutropenia
- 6.2.2 Anemia
- 6.2.3 Other hematology applications
- 6.3 Oncology
- 6.3.1 Lung cancer
- 6.3.2 Brain cancer
- 6.3.3 Breast cancer
- 6.3.4 Cervical cancer
- 6.3.5 Colorectal cancer
- 6.3.6 Leukemia
- 6.3.7 Other Oncology applications
- 6.4 Autoimmune disease
- 6.4.1 Arthritis
- 6.4.1.1 Rheumatoid arthritis
- 6.4.1.2 Psoriatic arthritis
- 6.4.1.3 Juvenile arthritis
- 6.4.1.4 Ankylosing spondylitis
- 6.4.1.5 Other arthritis
- 6.4.2 Inflammatory bowel disease (IBD)
- 6.4.2.1 Ulcerative colitis
- 6.4.2.2 Crohn's disease
- 6.4.2.3 Other IBD
- 6.4.3 Psoriasis
- 6.4.4 Other autoimmune diseases
- 6.4.1 Arthritis
- 6.5 Ophthalmology
- 6.6 Growth hormone deficiency
- 6.7 Diabetes
- 6.8 Other applications
Chapter 7 Market Estimates and Forecast, By Manufacturing Type, 2022-2035 ($ Mn)
- 7.1 Key trends
- 7.2 Contract research and manufacturing services
- 7.3 In-house
Chapter 8 Market Estimates and Forecast, By Technology, 2022-2035 ($ Mn)
- 8.1 Key trends
- 8.2 Recombinant DNA technology
- 8.3 Mammalian cell culture systems
- 8.4 Other technologies
Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2022-2035 ($ Mn)
- 9.1 Key trends
- 9.2 Hospital pharmacies
- 9.3 Specialty pharmacies
- 9.4 Other distribution channels
Chapter 10 Company Profiles
- 10.1 Aurobindo Pharma
- 10.2 Biocon Biologics
- 10.3 Dr. Reddy's Laboratories
- 10.4 Emcure Pharmaceuticals
- 10.5 Hetero Biopharma
- 10.6 Intas Pharmaceuticals
- 10.7 Lupin Limited
- 10.8 Reliance Life Sciences
- 10.9 Sun Pharmaceutical Industries
- 10.10 Torrent Pharmaceuticals
- 10.11 Viatris India
- 10.12 Wockhardt Limited
- 10.13 Zydus Lifesciences
- 10.14 Cadila Pharmaceuticals
- 10.15 Stelis Biopharma
